Is high-dose vitamin C the game-changer in cancer treatment that it's touted to be? Get the latest insights straight from the forefront of clinical research with the leading expert in the field. In this episode, we sit down with Dr. Joseph Cullen, a distinguished Professor of Surgery at the University of Iowa Carver College of Medicine. Dr. Cullen's groundbreaking clinical investigations center on the integration of high-dose vitamin C, also referred to as ascorbate or intravenous vitamin C (IVC), alongside conventional cancer therapies.

Drawing from his extensive experience, Dr. Cullen shared insights from several phase 1 and phase 2 clinical trials he has conducted. Notably, he discussed the groundbreaking results from the first-ever randomized IVC clinical trial which was conducted amongst pancreatic cancer patients. The trial's success was so remarkable that it was halted early, as it was deemed unethical not to offer IVC to all patients alongside standard care medications. These compelling findings have been submitted for publication and we are awaiting its release.

During our conversation, Dr. Cullen also shed light on similar clinical trials being conducted by him and his colleagues at the University of Iowa, targeting glioblastoma, non-small cell lung, and rectal cancers. These trials signify the growing recognition of IVC's potential as an adjunctive therapy in cancer treatment.

Delving into the science behind the efficacy of IVC, Dr. Cullen explained its mechanism of action and why it holds such promise in cancer therapy. His laboratory's research focuses on pharmacological ascorbate (P-AscH-, high dose, intravenous vitamin C) as an adjuvant to standard treatments, particularly for pancreatic cancer but he also addresses its potential for breast and prostate cancers.

With an impressive track record comprising 162 peer-reviewed papers and 32 book chapters, Dr. Cullen is at the forefront of advancing our understanding of IVC's role in cancer care. As the principal investigator of multiple clinical trials utilizing pharmacological ascorbate, he continues to spearhead innovative approaches to enhance cancer therapy through the manipulation of redox metabolism.

The Outperform Cancer podcast provides health information and should not be viewed as medical, nursing, or other professional healthcare advice. Listening to or engaging with the content does not create a doctor/patient relationship. Any reliance on the information from this podcast or linked materials is solely at your own discretion. This podcast's content is not meant to replace professional medical guidance, diagnosis, or care. If you have a medical issue or question, consult with a healthcare professional without delay.